Gilead Sciences, Inc. recently promoted Taiyin Yang to executive vice president for Pharmaceutical Development and Manufacturing, and Dr. Andrew Cheng to executive vice president of HIV Therapeutics and Development Operations.
“Andrew and Taiyin have both demonstrated leadership in bringing groups together to help expedite the development and manufacturing of products – ultimately allowing the company to reach patients in need more quickly,” Norbert Bischofberger, executive vice president of research and development and chief scientific officer for Gilead, said. “They are experts in their respective fields and have helped build teams that are efficient and highly productive. These promotions recognize their achievements and dedication to bringing innovative new therapies to patients around the world.”
Yang, a graduate of National Taiwan University and the University of Southern California, has worked for Gilead since 1993. In her new role, she is accountable for engineering clinical and commercial drug substance and drug product, and overseeing pharmaceutical development, analytical operations, laboratory information and quality assurance.
Cheng, a graduate of the University of California-Los Angeles, Colombia University and John Hopkins University, has been employed with Gilead since 1999. In 2009, Cheng was promoted to senior vice president of HIV Therapeutics and Development Operations. His added responsibilities will include biometrics, drug safety and public health, project management, regulatory affairs, clinical operations, and clinical pharmacology.